John Gribben

Professor
Barts Cancer Institute
Barts Cancer Institute, United Kingdom

N/A

Poster(s):

• 1206 - Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.